Interaction of Onset and Duration of Diabetes on the Percent of GAD and IA-2 Antibody–Positive Subjects in the Type 1 Diabetes Genetics Consortium Database
Open Access
- 21 March 2011
- journal article
- Published by American Diabetes Association in Diabetes Care
- Vol. 34 (4) , 988-993
Abstract
OBJECTIVE: GAD antibodies (GADA) are more common in type 1 diabetic subjects diagnosed at an older age, whereas insulinoma-antigen 2 antibodies (IA-2A) are more common in subjects with younger onset. The prevalence of both antibodies decreases with longer duration of type 1 diabetes. We evaluated the interaction between age of diagnosis (onset) and duration of diabetes on the percentage of GADA- and IA-2A–positive subjects. RESEARCH DESIGN AND METHODS: Data were used from 5,020 individuals with type 1 diabetes obtained from the Type 1 Diabetes Genetics Consortium dataset. The percentages of GADA- and IA-2A–positive subjects were modeled with duration as the continuous independent variable using a modified spline. RESULTS: Within the first 5 years from diagnosis, 19.4% of individuals (median age 13 years) had neither GADA nor IA-2A, and by 6 to 13 years after diagnosis (median age 18 years), 31.7% were antibody-negative. There was no significant interaction between onset of disease and duration of diabetes for IA-2A (P = 0.30). The interaction was significant for GADA (P = 0.0002), resulting from differences in subjects diagnosed at or older than age 14. For these individuals, there was no apparent effect of duration of disease on the percentage of GADA-positive subjects within the first 5 years of diagnosis. CONCLUSIONS: Onset and duration of diabetes both have an important effect on antibody status. The interaction of onset and duration on GADA positivity, but not on IA-2A, suggests differences in biology. These data provide a context for clinicians to interpret results of autoantibody testing in clinical practice.Keywords
This publication has 18 references indexed in Scilit:
- The effect of the MHC locus on autoantibodies in type 1 diabetesJournal of Medical Genetics, 2009
- C‐peptide in the natural history of type 1 diabetesDiabetes/Metabolism Research and Reviews, 2009
- Best practice guidelines for the molecular genetic diagnosis of maturity-onset diabetes of the youngDiabetologia, 2008
- The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetesProceedings of the National Academy of Sciences, 2007
- The Type 1 Diabetes Genetics ConsortiumAnnals of the New York Academy of Sciences, 2006
- Humoral beta‐cell autoimmunity in relation to HLA‐defined disease susceptibility in preclinical and clinical type 1 diabetesAmerican Journal of Medical Genetics, 2002
- Autoimmune type 1 diabetes: resolved and unresolved issuesJournal of Clinical Investigation, 2001
- Antiislet autoantibodies usually develop sequentially rather than simultaneouslyThe Journal of Clinical Endocrinology & Metabolism, 1996
- Glutamate decarboxylase-, insulin-, and islet cell-antibodies and HLA typing to detect diabetes in a general population-based study of Swedish children.Journal of Clinical Investigation, 1995
- Radioimmunoassay Detects the Frequent Occurrence of Autoantibodies to the Mr 65,000 Isoform of Glutamic Acid Decarboxylase in Japanese Insulin-Dependent DiabetesAutoimmunity, 1994